Cover Image
市場調查報告書

體形矯正:醫療設備的開發平台評估

Body Contouring - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 189545
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
體形矯正:醫療設備的開發平台評估 Body Contouring - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年03月16日 內容資訊: 英文 80 Pages
簡介

本報告提供體形矯正的開發中產品調查分析,以各開發階段的比較分析為焦點,提供開發中產品的主要企業,進行中的臨床試驗相關資訊等系統性資訊。

第1章 目錄

第2章 簡介

  • 體形矯正概要

第3章 開發中的產品

  • 體形矯正 - 開發中產品:各開發階段
  • 體形矯正 - 開發中產品:各地區
  • 體形矯正 - 開發中產品:各法規
  • 體形矯正 - 開發中產品:各核准預定日

第4章 體形矯正 - 正在開發的開發中產品:各企業

  • 體形矯正企業 - 開發中產品:各開發階段
  • 體形矯正 - 開發中產品:各開發階段

第5章 體形矯正企業與產品概要

  • Andrew Technology, LLC
  • b2medical GmbH
  • Biosculpture Technology, Inc.
  • Chromogenex Technologies Limited
  • Invasix
  • NivaSonix, LLC
  • Slender Medical Ltd.
  • Syneron Medical Ltd.
  • Yolo Medical Inc.
  • Zeltiq Aesthetics, Inc.

第6章 體形矯正 - 最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0312EPD

GlobalData's Medical Devices sector report, "Body Contouring - Medical Devices Pipeline Assessment, 2017" provides an overview of Body Contouring currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and the number of trials for the key Body Contouring pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Body Contouring under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Body Contouring and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Body Contouring under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Body Contouring Overview 6

3 Products under Development 7

  • 3.1 Body Contouring - Pipeline Products by Stage of Development 7
  • 3.2 Body Contouring - Pipeline Products by Territory 8
  • 3.3 Body Contouring - Pipeline Products by Regulatory Path 9
  • 3.4 Body Contouring - Pipeline Products by Estimated Approval Date 10

4 Body Contouring - Pipeline Products under Development by Companies 11

  • 4.1 Body Contouring Companies - Pipeline Products by Stage of Development 11
  • 4.2 Body Contouring - Pipeline Products by Stage of Development 12

5 Body Contouring Companies and Product Overview 13

  • 5.1 Andrew Technology LLC Company Overview 13
    • 5.1.1 Andrew Technology LLC Pipeline Products & Ongoing Clinical Trials Overview 13
  • 5.2 Biosculpture Technology, Inc. Company Overview 15
    • 5.2.1 Biosculpture Technology, Inc. Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.3 NivaSonix, LLC Company Overview 17
    • 5.3.1 NivaSonix, LLC Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.4 Slender Medical Ltd. Company Overview 18
    • 5.4.1 Slender Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.5 Zeltiq Aesthetics Inc Company Overview 19
    • 5.5.1 Zeltiq Aesthetics Inc Pipeline Products & Ongoing Clinical Trials Overview 19

6 Body Contouring- Recent Developments 22

  • 6.1 Mar 03, 2017: ZELTIQ Showcases CoolAdvantage Petite Applicator for the CoolSculpting System at American Academy of Dermatology Annual Meeting 22
  • 6.2 Mar 01, 2017: Syneron Candela Showcases UltraShape Power System at the 2017 American Academy of Dermatology (AAD) Annual Meeting 22
  • 6.3 Mar 01, 2017: ZELTIQ Announces Fourth Quarter and Full Year 2016 Financial Results 23
  • 6.4 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 24
  • 6.5 Feb 15, 2017: Syneron Medical Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue $298.1 Million 28
  • 6.6 Feb 13, 2017: Allergan to Acquire Zeltiq Aesthetics for USD2.48 Billion 29
  • 6.7 Feb 13, 2017: Cutera Reports Fourth Quarter and Full-Year 2016 Record Revenue and Financial Results 29
  • 6.8 Jan 31, 2017: Syneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources Officer 30
  • 6.9 Jan 26, 2017: CoolSculpting Announces Only FDA-Cleared Non-Invasive Treatment for Upper Arm Fat 31
  • 6.10 Jan 09, 2017: ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2016 Revenue and Provides 2017 Guidance 32
  • 6.11 Jan 09, 2017: ZELTIQ Aesthetics Announces Commercial Leadership Transition 33
  • 6.12 Jan 09, 2017: Cutera Names James A. Reinstein as its Next President and CEO 34
  • 6.13 Jan 09, 2017: Cutera Announces Record Revenue and Preliminary Financial Results for Fourth Quarter and Full Year 2016 35
  • 6.14 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 35
  • 6.15 Dec 29, 2016: Cytori Therapeutics Plans to Raise Funds through Public Offering of Shares 36
  • 6.16 Dec 28, 2016: Ronald Martell to Join Cytori Therapeutics' Board of Directors 36
  • 6.17 Dec 22, 2016: Cytori Therapeutics to Raise up to USD20 Million in Private Placement of Shares 36
  • 6.18 Dec 14, 2016: NJ Plastic Surgeon Presents on Fat Transfer Using the HyrdaSolve Lipoplasty System at IFATS San Diego 2016 37
  • 6.19 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 37
  • 6.20 Nov 29, 2016: Lutronic Raises USD43.7 Million in Rights Offering of Preferred Shares 38
  • 6.21 Nov 14, 2016: Andrew Technologies to Feature Two Powerful New Studies at IFATS San Diego 2016 39
  • 6.22 Nov 09, 2016: ZELTIQ Announces Third Quarter 2016 Financial Results 40
  • 6.23 Nov 09, 2016: Syneron Medical Reports Third Quarter 2016 Revenue of $71.5 Million 41
  • 6.24 Nov 09, 2016: Cytori Reports Third Quarter 2016 Business and Financial Results 42
  • 6.25 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 43
  • 6.26 Nov 07, 2016: Cutera Reports Record Third Quarter 2016 Results 46
  • 6.27 Nov 03, 2016: Cutera Elects J. Daniel Plants as Chairman of the Board 47
  • 6.28 Oct 26, 2016: Clarity Skin First In Utah To Offer Breakthrough, FDA-Cleared, Non-Invasive, UltraShape Power System For Fat Destruction 47
  • 6.29 Oct 26, 2016: Center City Dermatology First In Center City Philadelphia To Offer Breakthrough, FDA-Cleared, Non-Invasive, UltraShape Power System For Fat Destruction 48
  • 6.30 Oct 25, 2016: First MedSpa in Dallas-Fort Worth to Offer Breakthrough, FDA-cleared, Non-Invasive, UltraShape Power System For Fat Destruction 49
  • 6.31 Oct 17, 2016: Syneron Medical Strengthens Senior Management Team 49
  • 6.32 Oct 17, 2016: Syneron Medical Announces Preliminary Third Quarter 2016 Revenue 50
  • 6.33 Oct 17, 2016: Andrew Technologies Announces World's First Successful Mesenteric Fat Extraction, a Long-Awaited Breakthrough for Potential Reversal of Diabetes 50
  • 6.34 Oct 12, 2016: Clarkston Dermatology First In Michigan To Offer Breakthrough, FDA-Cleared, Non- Invasive, UltraShape Power System For Fat Destruction 51
  • 6.35 Oct 11, 2016: Cutera Announces Preliminary Record Third Quarter 2016 Revenue 52
  • 6.36 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 52
  • 6.37 Oct 04, 2016: LaserMed Skin & Vein Clinic First In Southeast To Offer Breakthrough, FDA-Cleared, Non-Invasive, UltraShape Power System For Fat Destruction 53
  • 6.38 Sep 19, 2016: Two New Studies Demonstrate Advantages of Andrew Technologies' HydraSolve as the Company Heads to ASPS 2016 54
  • 6.39 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 55
  • 6.40 Aug 18, 2016: Cutera Announces Management Changes 56
  • 6.41 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 56
  • 6.42 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 56
  • 6.43 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 58
  • 6.44 Aug 08, 2016: ZELTIQ Announces Second Quarter 2016 Financial Results 60
  • 6.45 Aug 04, 2016: Syneron Medical Reports Second Quarter 2016 Revenue of $75.0 Million and Non-GAAP EPS of $0.09 61
  • 6.46 Aug 04, 2016: Cytori Reports Second Quarter 2016 Business and Financial Results 63
  • 6.47 Aug 01, 2016: Cutera Reports Second Quarter 2016 Results 64
  • 6.48 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 65
  • 6.49 Jul 18, 2016: Syneron Candela Announces FDA Clearance of High Energy UltraShape Power for Fat Destruction 66
  • 6.50 Jun 27, 2016: ZELTIQ Announces Global Commercial Launch of the CoolAdvantage Applicator for the CoolSculpting System 67
  • 6.51 Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 68
  • 6.52 Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 68
  • 6.53 Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 69
  • 6.54 May 26, 2016: Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 70
  • 6.55 May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 70
  • 6.56 May 19, 2016: Syneron Medical Reports First Quarter 2016 Revenue of $68.7 Million 71
  • 6.57 May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters 72
  • 6.58 May 10, 2016: Cytori Reports First Quarter 2016 Business and Financial Results 73
  • 6.59 May 10, 2016: ZELTIQ Announces First Quarter 2016 Financial Results 74
  • 6.60 Mar 31, 2016: Alma Lasers to Launch Accent Prime, a Cutting-Edge Platform which Doubles the Speed of Body Contouring and Skin Tightening Treatments 76

7 Appendix 77

  • 7.1 Methodology 77
  • 7.2 About GlobalData 80
  • 7.3 Contact Us 80
  • 7.4 Disclaimer 80

List of Tables

1.1 List of Tables

  • Table 1: Body Contouring - Pipeline Products by Stage of Development 7
  • Table 2: Body Contouring - Pipeline Products by Territory 8
  • Table 3: Body Contouring - Pipeline Products by Regulatory Path 9
  • Table 4: Body Contouring - Pipeline Products by Estimated Approval Date 10
  • Table 5: Body Contouring Companies - Pipeline Products by Stage of Development 11
  • Table 6: Body Contouring - Pipeline Products by Stage of Development 12
  • Table 7: Andrew Technology LLC Pipeline Products & Ongoing Clinical Trials Overview 13
  • Table 8: HydraSolve Lipoplasty System - Visceral Fat - Product Status 13
  • Table 9: HydraSolve Lipoplasty System - Visceral Fat - Product Description 14
  • Table 10: Biosculpture Technology, Inc. Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 11: Airbrush Liposculptor IIE - Product Status 15
  • Table 12: Airbrush Liposculptor IIE - Product Description 15
  • Table 13: Airbrush Liposculptor IIIE - Product Status 16
  • Table 14: Airbrush Liposculptor IIIE - Product Description 16
  • Table 15: NivaSonix, LLC Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 16: NivaSonix ULLISYS - Product Status 17
  • Table 17: NivaSonix ULLISYS - Product Description 17
  • Table 18: Slender Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 19: Ultrasound Body Shaping Device - Product Status 18
  • Table 20: Ultrasound Body Shaping Device - Product Description 18
  • Table 21: Zeltiq Aesthetics Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 22: CoolAdhesive Gelpad - Product Status 19
  • Table 23: CoolAdhesive Gelpad - Product Description 20
  • Table 24: CoolAdvantage Petite Applicator - Product Status 20
  • Table 25: CoolAdvantage Petite Applicator - Product Description 20
  • Table 26: Zeltiq Applicator - Cellulite - Product Status 21
  • Table 27: Zeltiq Applicator - Cellulite - Product Description 21
  • Table 28: Glossary 79

List of Figures

1.2 List of Figures

  • Figure 1: Body Contouring - Pipeline Products by Stage of Development 7
  • Figure 2: Body Contouring - Pipeline Products by Territory 8
  • Figure 3: Body Contouring - Pipeline Products by Regulatory Path 9
  • Figure 4: Body Contouring - Pipeline Products by Estimated Approval Date 10
Back to Top